Waldenström Macroglobulinemia

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Anal Cancer

Colorectal Cancer

Esophageal Cancer

Gallbladder Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Testicular Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Uterine Cancer

Vulvar Cancer

Gynecologic Cancer

Head & Neck Cancer

Immunotherapy

Acute Myeloid Leukemia

Leukemia

Mesothelioma

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Small Lymphocytic Lymphoma (SLL)

Lymphoma

Myeloma

Cancer of Unknown Primary

Carcinoid Cancer

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Melanoma

Skin Cancer

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

The lymphoma cancer condition center is a comprehensive resource for cancer news & oncologist insights on lymphoma cancer. Read more about cancer at CURE.

Lymphoma Cancer | Oncology & Cancer News | CURE

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of the cancer experience.

About

Advertise / Support

Contact

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

Tumor

CURE’s lymphoma cancer page is a go-to resource for oncology news and updates in the world of lymphoma cancer Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in lymphoma cancer.

Last week, we saw some big headlines in the oncology space, from Dexter Scott King’s death from prostate cancer and MLB Hall-of-Famer Ryne Sandberg announcing that he was diagnosed with the disease.

The FDA also requested a label update for CAR-T cell therapies that would warn patients and providers about secondary malignancies that have been reported from the treatment. Also, we took a look at laughter therapy, and how it could help patients and caregivers.

We’ve also been busy covering two conferences — ASCO’s 

, so tune in later this week for a special podcast episode highlighting some major research from those events.

Dexter Scott King Dies of Prostate Cancer, Ryne Sandberg Diagnosed With the Disease

Last Monday, Jan. 22, we saw two big stories in the prostate cancer space. First, Dexter Scott King, the son of the Civil Rights activist, Martin Luther King, Jr., died of prostate cancer. He was 62 years old.

At the time of his death, King was the Chairman of the King Center, which is an organization focused on educating the world about the life and legacy of Dr. Martin Luther King Jr. Dexter Scott King was also the president of the King estate.

In a statement announcing King’s death, his wife, Leah Weber said, “He transitioned peacefully in his sleep at home with me in Malibu. He gave it everything and battled this terrible disease until the end.”

And on the same day Dexter Scott King died, Major League Baseball Hall-of-Famer, Ryne Sandberg, announced that he was diagnosed with metastatic prostate cancer.

The 64-year-old — who was a 10-time All Star during his tenure for the Chicago Cubs, which ran from 1982 to 1997 — announced his diagnosis on Instagram. He said that received the diagnosis a week earlier and has started treatment. He asked that fans keep him in their thoughts and prayers.

FDA Requests Warnings on CAR-T Cell Therapies, Citing Secondary Cancers

The investigation into CAR-T cell therapies continues. Recently, the Food and Drug Administration (FDA) requested that approved BCMA- or CD19-targeted CAR-T cell therapies update their labeling to include a warning of reports of T-cell malignancies, including CAR-positive lymphomas, which have been reported in patients who use this type of therapy.

Back in November, the FDA announced that it was investigating 

reports of secondary diseases in patients who underwent CAR-T cell therapy

. The available data shows that these diseases are extremely rare, and researchers are still looking into what, exactly, is causing them.

Now, the FDA wrote letters to the manufacturers of five CAR-T cell therapies, requesting that they include a Boxed Warning — which is the highest safety-related warning for drugs — outlining the potential risks of CAR-T cell products. The companies must respond to the FDA within 30 days of receiving the letters, which were sent out on Jan. 19.

Laughter Therapy May Improve Mood, Decrease Pain in Patients With Cancer

And on a much lighter note, we covered recent research showing that laughter therapy can decrease mood disturbances in patients receiving palliative care for late-stage cancer, as well as their loved ones. The findings, which were published in the journal, 

, also found that the laughter therapy reduced pain perception in patients and decreased levels of burnout in caregivers.

Laughter therapy refers to alternative and complementary therapy using humor to help relieve stress and pain, in addition to potentially improving a patient’s sense of well-being, according to the National Cancer Institute. In this instance, it consisted of five 20- to 30-minute sessions held over five consecutive days. The participants introduced themselves using funny tools to relieve tension, and moved their bodies in laughing rhythms.

“This indicates that our palliative care patients and family caregivers would have a positive view of the use of laughter or humor in their palliative circumstances,” the researchers wrote.

For more news on cancer updates, research and education, don’t forget to 

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Blood cancer treatments — and one treatment type, in particular — were the point of much discussion last week. The FDA said that it is investigating instances of secondary malignancies in patients with blood cancers treated with CAR-T cell therapy. Also, the drug manufacturer for a novel CAR-T cell therapy submitted an application to introduce the treatment into the United States market.

Blood cancers will continue to be a hot topic this week, as later in the week we’ll be covering the American Society of Hematology Annual Meeting. And before that, we’ll also be covering the San Antonio Breast Cancer Symposium.

Chance or CAR-T: Expert Weighs in on FDA Investigation

One of the biggest headlines in the cancer space last week was that the Food and Drug Administration (FDA) announced that they are investigating instances of T-cell malignancies — such as CAR-positive lymphoma — occurring in patients with blood cancers that were treated with CAR-T cell therapy.

CAR-T cell therapy is a newer type of blood cancer treatment that involves extracting patients’ blood and reengineering their immune T cells to find and fight cancer. Those new T cells are then multiplied and infused back into the patient. Since the first CAR-T cell product was approved in 2017, this treatment modality has drastically improved outcomes for patients with certain types of blood cancers.

It’s worth mentioning that the FDA’s Nov. 28 report about T-cell malignancies did not definitively say that CAR-T cell therapies are directly causing secondary diseases. They also did not mention the frequency at which these T-cell malignancies are occurring. I spoke with Dr. John Lister, who said that perhaps it’s the manufacturing process that could be the root cause, but perhaps it is also just chance, as research has shown that many patients with cancer hold a higher risk of developing a second cancer. For now, we’re just going to have to wait and see what further data tells us.

FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL

Also in CAR-T cell therapy news, last week a pharmaceutical company submitted a Biologics License Application to the FDA for their CAR-T cell therapy, obe-cel to be used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

When a pharmaceutical company files a Biologics License Application to the FDA, they’re essentially asking the agency to allow them to bring the drug to the market. The company submitting the drug must provide the FDA with multiple pieces of information, including findings from preclinical and clinical studies showing that the drug is safe.

In this instance, the pharmaceutical company cited data from the FELIX study, from which, early data showed that 76% if patients responded to the therapy, including 54.3% who had a complete response, meaning that their disease essentially disappeared. Now, updated findings from the trial will be presented at the upcoming ASH Annual Meeting. 

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week. 

Top Headlines on CAR-T Cell Therapy

Bill C. Potts, author of the book “Up for the Fight,” lends his experiences and knowledge about cancer to his readers as a five-time cancer survivor.

“In September of 2020, I woke up from surgery to remove a really painful tumor in below my right hip,” Potts told 

 during an exclusive interview. “And I had an emotional breakdown, when I was waking up from the surgery in the recovery room, and they called in the pastor and we talked through a lot of things, including the reasons why I should continue to fight the battle. And at the end of that conversation, the pastor told me that I should turn my pain into purpose and write a book to help others.”

In 2002, at 42 years old, Potts received a diagnosis of thyroid cancer. Since then, he has experienced four cases of lymphoma and, most recently, received a diagnosis of prostate cancer. Potts knew he needed to share his story with others, so during chemotherapy treatments, he picked up his laptop and began writing. He grasped the opportunity to urge fellow patients to advocate for themselves, as he learned to do.

Potts, at 63 years old, recently celebrated two years in remission and chooses to live in the moment, spending each day doing what he wants to do.

In this episode of the “Cancer Horizons” podcast, Potts speaks with 

 about his cancer journey and his book “Up for the Fight.”

“I'd kept my cancer (a) secret until the book came out. And now that the book is out, it's challenging at times, because it's hard to talk about,” he said. “Sometimes it can be triggering to talk about it, but mostly what I find is that it's rewarding, and the impact that it's having on other cancer patients. So, I would say that it's a responsibility.”

Since sharing his story through writing his book, others with similar experiences have also picked it up, which Potts said was encouraging. It further motivated him to promote his book as a guide for patients and their families. Potts told 

 that he especially wanted to promote the book to patients experiencing cancer right after being diagnosis, “so that it can make a difference in their journey.”

Potts explained that he didn’t have guides to turn to when he was first diagnosed, and emphasized how this book was one he wished someone else had written for him. Or, as he describes it, “there really wasn’t that how-to guide out there, like ‘What to Expect When You’re Expecting,’ but for cancer.”

Now, the book has become Potts’ purpose.

Potts admitted that he didn’t “own his journey” when he was first diagnosed with thyroid cancer. “I let the doctors tell me what to do, and that that decision still may cost me my life,” he said. “So, the first thing is that you have to create the mindset, that this is me, it's my job. And the key part is the job part, to get better and to own the journey, that it's a little bit counterintuitive to a lot of people that you own your journey, not the healthcare team. But the healthcare team appreciates a patient that owns their journey.”

In “Up for the Fight,” Potts stresses to his readers that owning their journeys and advocating for themselves is necessary. He told 

 some tips that worked for him: research potential cancer treatment centers, get a second opinion, take notes during appointments, build relationships with care teams, communicate with doctors and care teams, research the drugs and treatments that will be used and ensure proper mental and emotional support.

“I do that through groups on Facebook, which is super helpful, but professional help, like therapists, things like that is also a great way to own your journey,” Potts said during the interview. “And I really have been lucky to get to know a lot of people through the book (who) are owning their journey and that also inspires me (and) gives me hope.”

Bill C. Potts, author and five-time cancer survivor, lends his experience and tips about cancer to others in his book, “Up for the Fight.”

Author, Five-Time Cancer Survivor Shares His Experiences in New Book

With recent research demonstrating that antibodies were not detected in some patients with B-cell blood cancers after receiving two doses of the COVID-19 vaccine, many people have questions. Will a third dose help these patients? Should they bother with the vaccine? How do their current cancer treatments impact the vaccine’s effectiveness?

Dr. Larry Saltzman, the executive research director at the Leukemia & Lymphoma Society, answered these questions and more in this episode of the “Cancer Horizons” podcast.

“So there's two swings of the pendulum, those who will respond in a global, very good way – not to worry, essentially, and those (who) will not respond due to the treatments that they're on,” Saltzman said.

The Leukemia & Lymphoma Society

An expert from the Leukemia & Lymphoma Society breaks down the effectiveness of the COVID-19 vaccine in patients with blood cancers on this episode of the “Cancer Horizons” podcast.

What Patients With Blood Cancers Need to Know About COVID-19, Booster Shots and More

Olympic triathlete Kevin McDowell has pushed his body to the limit in more than just athletics. He was diagnosed with Hodgkin’s lymphoma at a young age – a diagnosis that interrupted his training – and dealt with both physical and emotional repercussions for years after.

In this episode of the “CURE® Talks Cancer” podcast, McDowell discusses his cancer journey and shares some insight on his experiences at the Tokyo 2020 Olympics.

“In 2013 actually, two years after my treatment, I almost stepped away completely from the sport and was like ‘I can't do this anymore,’” McDowell said. “My body kept breaking down. I wasn't right. And so I actually put a focus on school and took five months away from the sport, and just did a little bit of activity, but nothing that was considered training. And then five months after, I was kind of ‘Hey, I actually want to maybe give another go at this triathlon thing.’”

In this episode of the “CURE® Talks Cancer” podcast, Olympic triathlete Kevin McDowell discusses his cancer journey and shares some insight on his experiences at the Tokyo 2020 Olympics.

The Olympic Silver Medalist Who Survived Cancer: Kevin McDowell Shares His Story

Steve Kelley is a professor, public speaker, grandfather and avid biker, among other things. But he is also living with central nervous system lymphoma, a rare cancer that his doctors told him is incurable and inoperable.

After being unable to find peers facing a similar diagnosis, Kelley decided to share his story in the book, “

In this episode of the “CURE® Talks Cancer” podcast, Kelley opens up about his cancer journey and offers others advice on how to get through life after receiving such a shattering diagnosis.

“If you can try to do (these) four things, M-A-T-H, do the math: meaning, action, trust and hope,” Kelley said. “You can do those things for the people in your life and for yourself. I think that will put you in this great place that enables you to couple that with grace, couple that with exercise, and now you're in a place that you can do the best you can with cancer.”

In this episode of the “CURE® Talks Cancer” podcast, author Steve Kelley shares both the painful and positive moments of his journey with a rare cancer.

Learning to Live with an Incurable, Inoperable Cancer

In 2017, Sonia Su was a 24-year-old graduate student at Georgetown University who dreamed of travelling abroad and working for the government.

During that time, she started experiencing chest pains. As her symptoms began to worsen, Su decided to visit the campus’ health center where she eventually received a diagnosis of costochondritis — inflammation of the cartilage that connects a person’s rib to their breastbone. Su was prescribed something for the pain, but her symptoms continued.

®, said she was amid finishing finals and decided to wait until she was done to get a second opinion at an urgent care facility. After multiple tests — which included CT scans, X-rays and a biopsy — Su received a diagnosis of stage 2 primary mediastinal large B-cell lymphoma. The journey that would follow, according to Su, taught her many life lessons that will stick with her.

® Talks Cancer Podcast,” she discusses how her disease recurred while she was on a fellowship in Taiwan and how her experiences led her to establish a nonprofit organization — called Kits to Heart — to give back to others who are also going through cancer.

“I was really inspired by my time when I was admitted for my final treatment two years ago ….,” she said. “I saw a care package that was left on my bed, and I had just assumed that it was, you know, part of the welcome package from the hospital. But it turns out, it was from a former patient who had been treated at that very unit one year prior and was doing well again. And so just seeing that message of hope really inspired me and motivated me to keep going. And I told myself right then and there that I would do the same thing once I got out of there. And so, I essentially took that idea to help solve those problems that I myself witnessed as a patient and founded what is now called Kits to Heart.”

In this episode of the “CURE® Talks Cancer” podcast, we spoke with a large B-cell lymphoma “alumni” who was diagnosed at 24 about what it was like to be the only young patient receiving infusions at her cancer center, and what led her to start a nonprofit organization to help others along their journey.

How a Handmade Care Package Inspired One Cancer ‘Alumni’ to Create ‘Kits to Heart’

In early 2020, 24-year-old Nina Luker was completely blindsided by lymphoma. The stage 4 diagnosis, in her words, felt like a “death sentence.” But while powering through treatments in the thick of the COVID-19 pandemic, Luker turned to social media to document and share her experience in a raw and unrehearsed way – and soon gained nearly 200,000 followers on 

, who identified with her situation and cheered her on at every step of the way.

Now officially cancer free, Luker joined us on the “CURE Talks Cancer” podcast to talk about her cancer journey, her work with the Lymphoma Research Foundation, and offer advice to those who may have recently received a diagnosis of their own.

Most notably, cancer has put her life into perspective, and helped her learn how to appreciate the little things. “If I could go back and change my life, I would keep cancer in the mix,” Luker said. “I would keep it because who I have become since that is a person who is more aware of what brings them joy, is more able to see the simple pleasures in life, and to treat people with the utmost respect because you don't know what they're going through.”

Nina Luker

This week on the “CURE® Talks Cancer” podcast, we spoke with lymphoma survivor Nina Luker about what it was like to receive a diagnosis at age 24, and how sharing her story with nearly 200,000 supporters on TikTok and Instagram led her to find purpose with the Lymphoma Research Foundation.

Lymphoma

Latest News